Mesalazine [5-aminosalicylic acid] interactions
Checked as Mesalazine in this data source.
Full monograph for Mesalazine [5-aminosalicylic acid]Check it against another medicine
Medicines
389 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adefovir Dipivoxil | Major | Excretion | Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 1 sources — open the full entry |
| Deferasirox | Major | Synergy | Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents… | 3 sources — open the full entry |
| Human Anti-D Immunoglobulins | Major | Synergy | Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available… | 11 sources — open the full entry |
| Iodixanol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Iohexol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Iopamidol | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Tacrolimus MonohydrateOralTopical | Major | Synergy | Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive… | 4 sources — open the full entry |
| Tenofovir Alafenamide | Major | Excretion | Coadministration of tenofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Additionally… | 8 sources — open the full entry |
| Tenofovir Disoproxil | Major | Excretion | Coadministration of tenofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Additionally… | 8 sources — open the full entry |
| AcyclovirInjectionOphthalmicOral | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Amikacin | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Amphotericin B | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Azathioprine | Moderate | Synergy | Aminosalicylate derivatives (e.g., balsalazide, mesalamine, olsalazine, sulfasalazine) may potentiate the pharmacologic effects of purine antagonist… | 8 sources — open the full entry |
| Bacitracin Zinc + Polymyxin B Sulfate | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic) | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Bromfenac Sodium | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculin | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculin | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Cisplatin | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Clobetasol Propionate + Neomycin Sulphate + Nystatin | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Colistimethate Sodium | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…3 documented mechanisms | 4 sources — open the full entry |
| Dexamethasone + Tobramycin | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Dexibuprofen | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Dexketoprofen | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Diclofenac Potassium | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Diclofenac Sodium | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Diclofenac Sodium + Methyl Salicylate + Linseed Oil + Menthol | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Diclofenac Sodium + Misoprostol | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Entecavir Monohydrate | Moderate | Excretion | Because entecavir is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of… | 2 sources — open the full entry |
| Etodolac | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Fluocinolone Acetonide + Neomycin Sulfate | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Fluormetholone + Neomycin Sulphate | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Fluorometholone + Gentamicin | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Flurbiprofen | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Gentamicin + Hydrocortisone Acetate | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Gentamicin SulfateInjectionOphthalmic | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Glibenclamide | Moderate | Synergy | The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors… | 112 sources — open the full entry |
| Glimepiride | Moderate | Synergy | The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors… | 112 sources — open the full entry |
| Glimepiride + Metformin | Moderate | Synergy · Unknown | The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors…2 documented mechanisms | 112 sources — open the full entry |
| Glipizide | Moderate | Synergy | The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors… | 112 sources — open the full entry |
| Glipizide + Metformin Hydrochloride | Moderate | Synergy · Unknown | The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors…2 documented mechanisms | 112 sources — open the full entry |
| Gramacidin + Neomycin + Polymixin B | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…2 documented mechanisms | 4 sources — open the full entry |
| Hydrocortisone + Neomycin Sulphate + Polymixin B | Moderate | Synergy · Unknown | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the…3 documented mechanisms | 4 sources — open the full entry |
Conditions
Conditions in which Mesalazine [5-aminosalicylic acid] needs care, as documented in this source.
Kidney Diseases
ModerateThe use of mesalamine and other compounds which contain or are converted to mesalamine has rarely been associated with renal adverse effects, including minimal change nephropathy, acute and chronic interstitial nephritis, and nephrogenic diabetes insipidus. Renal lesions such as renal infarct, papillary necrosis, tubular necrosis and interstitial fibrosis have been reported in high-dose animal studies. Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired renal function or a history of renal disease. Renal function should be evaluated prior to initiation of therapy and periodically during therapy.
10 sources
- Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442
- Mehta RP "Acute interstitial nephritis due to 5-aminosalicylic acid." Can Med Assoc J 143 (1990): 1031-2
- Masson EA, Rhodes JM "Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss." Gut 33 (1992): 563-4
- Thuluvath PJ, Ninkovic M, Calam J, Anderson M "Mesalazine induced interstitial nephritis." Gut 35 (1994): 1493-6
- "Product Information. Asacol (mesalamine)." Procter and Gamble Pharmaceuticals (2022):
- "Product Information. Rowasa (mesalamine)." Solvay Pharmaceuticals Inc (2022):
- "Product Information. Pentasa (mesalamine)." Hoechst Marion Roussel
- "Product Information. Dipentum (olsalazine)." Meda Pharmaceuticals (2001):
Show all 10 sourcesShow fewer sources
- Wilcox GM, Reynolds JR, Galvanek EG "Nephrotoxicity associated with olsalazine." Am J Med 100 (1996): 238-40
- "Product Information. Colazal (balsalazide)." Salix Pharmaceuticals (2001):
Liver Diseases
ModerateThe use of mesalamine and other compounds which contain or are converted to mesalamine has been associated with hepatic adverse effects, including hepatic failure. Therapy with mesalamine and prodrugs of mesalamine should be administered cautiously in patients with impaired hepatic function or a history of liver disease. Liver function should be evaluated prior to initiation of therapy and periodically during therapy.
2 sources
- "Product Information. Pentasa (mesalamine)." Hoechst Marion Roussel
- "Product Information. Lialda (mesalamine)." Shire US Inc (2022):